Lord, Abbett & Co
DNTH icon

Lord, Abbett & Co’s Dianthus Therapeutics DNTH Stock Holding History

Lord, Abbett & Co’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.2M Buy
422,185
+122,975
+41% +$10.7M 0.12% 209
2026
Q1 		$25.1M Buy
+299,210
New +$17.3M 0.08% 244

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Lord, Abbett & Co's DNTH Position: Q2 2026 in Review

Lord, Abbett & Co increased its Dianthus Therapeutics (DNTH) stake by 41% in Q2 2026, buying an estimated $10.7M and bringing the position to 422,185 shares worth $41.2M. The position accounts for 0.12% of the portfolio, ranked #209.

Lord, Abbett & Co first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Lord, Abbett & Co held 422,185 shares of Dianthus Therapeutics worth $41.2M as of Q2 2026.
  • Lord, Abbett & Co bought 122,975 Dianthus Therapeutics shares in Q2 2026, an estimated $10.7M.
  • Dianthus Therapeutics made up 0.12% of Lord, Abbett & Co's portfolio in Q2 2026, its #209 holding.
  • Lord, Abbett & Co first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.